PMID- 37162319
OWN - NLM
STAT- MEDLINE
DCOM- 20231129
LR  - 20240218
IS  - 1097-9891 (Electronic)
IS  - 0095-2990 (Print)
IS  - 0095-2990 (Linking)
VI  - 49
IP  - 5
DP  - 2023 Sep 3
TI  - Tusi: a new ketamine concoction complicating the drug landscape.
PG  - 546-550
LID - 10.1080/00952990.2023.2207716 [doi]
AB  - A drug concoction called tusi has emerged in Latin America and in Europe and is 
      now beginning to acquire popularity in the United States. "Tusi" is a phonetic 
      translation of "2C," a series of psychedelic phenethylamines. The concoction is 
      also sometimes referred to as "pink cocaine" as it typically comes in the form of 
      pink powder. However, despite its name, the concoction rarely contains 2C series 
      drugs. Multiple drug checking studies have found that the majority of tusi 
      samples contain ketamine, often combined with 3,4-methylenedioxymethamphetamine 
      (MDMA), methamphetamine, cocaine, opioids, and/or new psychoactive substances. 
      The tusi phenomenon complicates the drug landscape because it has the potential 
      to confuse both people who use it and researchers alike. People using may think 
      the drug is 2C/2C-B, and they may also be unaware that the concoction tends to 
      consist of ketamine and a wide variety of other drugs. Unintentional exposure to 
      its contents can lead to increased risk of adverse effects. The tusi phenomenon 
      also has the potential to complicate drug research as unknown exposure to drugs 
      like ketamine and MDMA will lead to underreporting of use. A combination of 
      self-report and toxicological testing may be needed to inform the most accurate 
      estimates of use. Both researchers and people at risk for use need to be informed 
      about this new concoction. Drug researchers need to be cognizant about the way 
      they query use, and people at risk for using need to be educated about the 
      possible contents of tusi and associated dangers.
FAU - Palamar, Joseph J
AU  - Palamar JJ
AD  - Department of Population Health, New York University Grossman School of Medicine, 
      New York, NY, USA.
LA  - eng
GR  - R01 DA044207/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230510
PL  - England
TA  - Am J Drug Alcohol Abuse
JT  - The American journal of drug and alcohol abuse
JID - 7502510
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - 690G0D6V8H (Ketamine)
RN  - 0 (Hallucinogens)
RN  - 44RAL3456C (Methamphetamine)
RN  - I5Y540LHVR (Cocaine)
SB  - IM
MH  - Humans
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
MH  - *Ketamine/adverse effects
MH  - *Hallucinogens
MH  - *Methamphetamine
MH  - *Cocaine
MH  - *Substance-Related Disorders/epidemiology
PMC - PMC10636235
MID - NIHMS1899644
OTO - NOTNLM
OT  - Tusi
OT  - club drugs
OT  - ketamine
OT  - new psychoactive substances
COIS- Disclosure statement No potential conflict of interest was reported by the 
      author(s).
EDAT- 2023/05/10 12:42
MHDA- 2023/11/29 06:42
PMCR- 2024/09/03
CRDT- 2023/05/10 09:53
PHST- 2024/09/03 00:00 [pmc-release]
PHST- 2023/11/29 06:42 [medline]
PHST- 2023/05/10 12:42 [pubmed]
PHST- 2023/05/10 09:53 [entrez]
AID - 10.1080/00952990.2023.2207716 [doi]
PST - ppublish
SO  - Am J Drug Alcohol Abuse. 2023 Sep 3;49(5):546-550. doi: 
      10.1080/00952990.2023.2207716. Epub 2023 May 10.